Zalicus Initiates Phase 1b Clinical Study of Z944, Its Novel, Oral, T-type Calcium Channel Blocker, for the Treatment ... Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has initiated a Phase 1b clinical study with Z944, its novel oral T-type calcium channel blocker, in an experimental clinical model of neuropathic pain using Laser-Evoked Potentials .
Sept. 9, 2013 - Business Wire via Yahoo! Finance